08.01.2024 13:30:00
|
Tecan to present at upcoming Investor Conferences
Männedorf, Switzerland, January 8, 2024 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences this week:
42nd Annual J.P. Morgan Healthcare Conference, San Francisco
Date: 10 January 2024
Presentation: 09:00 am PST (6:00 pm CET)
Presenter: Dr. Achim von Leoprechting, CEO, Tecan
Additional participant: Tania Micki, CFO
Webcast live under the "Investor Relations" tab of Tecan's website www.tecan.com
A replay of the webcast will be available after the presentation and will remain available for 30 days.
Baader Helvea Swiss Equities Conference, Bad Ragaz
Date: 11 January 2024
Participants: Klaus Lun, EVP, Head of the Life Sciences Business division
Ralf Griebel, EVP, Head of the Partnering Business division
Martin Brändle, SVP, Corp. Comm. & Investor Relations
Not webcasted
Octavian Seminar 2024, Davos
Date: 12 January 2024
Participants: Klaus Lun, EVP, Head of the Life Sciences Business division
Ralf Griebel, EVP, Head of the Partnering Business division
Martin Brändle, SVP, Corp. Comm. & Investor Relations
Not webcasted
About Tecan
Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,500 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2022, Tecan generated sales of CHF 1,144 million (USD 1,192 million; EUR 1,144 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Martin Braendle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
Attachment


Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Tecan (N)mehr Nachrichten
25.02.25 |
SPI-Titel Tecan (N)-Aktie: So viel Verlust hätte ein Tecan (N)-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
20.02.25 |
Börse Zürich in Grün: SPI am Donnerstagmittag stärker (finanzen.at) | |
20.02.25 |
Zurückhaltung in Zürich: SPI präsentiert sich zum Start schwächer (finanzen.at) | |
18.02.25 |
SPI-Titel Tecan (N)-Aktie: So viel Verlust wäre bei einem Investment in Tecan (N) von vor 3 Jahren angefallen (finanzen.at) | |
11.02.25 |
SPI-Wert Tecan (N)-Aktie: So viel Verlust hätte eine Investition in Tecan (N) von vor einem Jahr bedeutet (finanzen.at) | |
04.02.25 |
SPI-Papier Tecan (N)-Aktie: So viel Gewinn hätte ein Investment in Tecan (N) von vor 10 Jahren eingefahren (finanzen.at) | |
28.01.25 |
Aufschläge in Zürich: So bewegt sich der SPI mittags (finanzen.at) | |
28.01.25 |
SPI-Papier Tecan (N)-Aktie: So viel Verlust wäre bei einem Investment in Tecan (N) von vor 5 Jahren angefallen (finanzen.at) |
Analysen zu Tecan (N)mehr Analysen
Aktien in diesem Artikel
Tecan (N) | 229,00 | 13,59% |
|